

101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information  
**Olerup SSP® HLA-C\*15**

<b>Product number:</b>	101.626-12 – including <i>Taq</i> polymerase 101.626-12u – without <i>Taq</i> polymerase
<b>Lot number:</b>	0R9
<b>Expiry date:</b>	2026-07-01
<b>Number of tests:</b>	12
<b>Number of wells per test:</b>	43+1
<b>Storage - pre-aliquoted primers:</b>	dark, between -15°C and -25°C
- PCR Master Mix:	between -15°C and -25°C
- Adhesive PCR seals	RT

**This Product Description is only valid for Lot No. 0R9.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP®  
HLA-C\*15 LOT (8K0)**

- The product documentation has been updated for new alleles of IMGT 3.48.0.
- The kit resolution focuses on common and well documented (CWD) alleles<sup>1</sup>.
- 2 new wells were added, wells 43 and 44.

<sup>1</sup>As described in section Uniquely Identified Alleles.

The HLA-C\*15 primer set, specificity and interpretation tables have been updated for the HLA-C alleles described since the previous *Olerup SSP®* HLA-C\*15 lot was made (Lot No. 8K0).

<sup>1</sup>S. J. Mack, P. Cano, J. A. Hollenbach et al.  
Common and well-documented HLA alleles: 2012 update to  
the CWD catalogue. *Tissue Antigens*, 2013, 81, 194–203



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

**Lot-specific information**

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
25	-	Added	3'-primer added for the C*15:52:02 allele.
42	Added	Added	Primer pair added for the C*15:57 allele. Negative control moved to well 44.
43	New	New	New primer pair for the C*15:72 allele.
44	Added	Added	Negative control added from well 42.



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

**Lot-specific information**

Well **44** contains Negative Control primer pairs, will amplify the majority of the Olerup SSP<sup>®</sup> HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							<b>36</b>
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							<b>48</b>
							5'-gCA <sup>3'</sup>
							<b>48</b>
							5'-gCC <sup>3'</sup>
							<b>52</b>
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information

## PRODUCT DESCRIPTION

### HLA-C\*15 SSP typing

#### CONTENT

The primer set contains 5'- and 3'-primers for identifying the C\*15:02 to C\*15:250 alleles.

#### PLATE LAYOUT

Each HLA-C\*15 test consists of 44 PCR reactions in a 48 well cut PCR plate. Wells 45 to 48 are empty.

<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>
<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>
<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>
<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>31</b>	<b>32</b>
<b>33</b>	<b>34</b>	<b>35</b>	<b>36</b>	<b>37</b>	<b>38</b>	<b>39</b>	<b>40</b>
<b>41</b>	<b>42</b>	<b>43</b>	<b>NC</b>	empty	empty	empty	empty

The 48 well PCR plate is marked with ‘HLA-C\*15’ in silver/gray ink.

Well No. 1 is marked with the Lot No. ‘0R9’.

Wells 1 to 43 – HLA-C\*15 high resolution primers.

Well 44 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays and should be disregarded.

The PCR plates are heat-sealed with a PCR-compatible foil.

**Please note:** When removing each 48 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

#### INTERPRETATION

Due to the sharing of sequence motifs between HLA-C alleles non-HLA-C\*15 alleles will be amplified by some primer mixes. For further details see Specificity Table.

#### UNIQUELY IDENTIFIED ALLELES

All the HLA-C\*15 alleles, i.e. **C\*15:02 to C\*15:250**, recognized by the HLA Nomenclature Committee in April 2022<sup>1,2</sup> will be amplified by the primers in the HLA-C\*15 SSP kit<sup>3</sup>.

The HLA-C\*15 kit enables separation of the confirmed HLA-C\*15 alleles as listed in the IMGT/HLA database 3.26.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-C\*15 alleles is listed below.



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

**Lot-specific information**

The HLA-C\*15 kit also enables identification of many null and alternatively expressed alleles.

The following HLA-C\*15 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix	Alleles	Primer mix
C*15:18, 15:118, 15:138	9	C*15:35, 15:47	21
C*15:32Q, 15:41	24	C*15:44:01-15:45	20
C*15:33, 15:84Q	28	C*15:46, 15:111, 15:201	19
C*15:34, 15:39, 15:130	17	C*15:81, 15:96Q	29

<sup>1</sup>HLA-C alleles listed on the IMGT/HLA web page 2022-April-19, release 3.48.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

<sup>3</sup>The following alleles cannot be separated by the HLA-C\*15 kit. These alleles can be distinguished by the HLA-C low resolution kit and/or the HLA-C\*16 high resolution kit.

**Alleles**

C\*15:04:01:01-15:04:06, 15:211, 15:236, C\*16:70



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information

**ALLELE CONFIRMATION STATUS**

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
C*15:02:01:01	Confirmed	C*15:09	Confirmed	C*15:58	Confirmed	C*15:107	Unconfirmed
C*15:02:01:02	Unconfirmed	C*15:10:01	Unconfirmed	C*15:59	Unconfirmed	C*15:108	Confirmed
C*15:02:01:03	Unconfirmed	C*15:10:02	Confirmed	C*15:60	Unconfirmed	C*15:109	Unconfirmed
C*15:02:02	Unconfirmed	C*15:10:03	Unconfirmed	C*15:61	Unconfirmed	C*15:110	Unconfirmed
C*15:02:03	Confirmed	C*15:11	Confirmed	C*15:62	Unconfirmed	C*15:111	Unconfirmed
C*15:02:04	Confirmed	C*15:12	Unconfirmed	C*15:63	Unconfirmed	C*15:112	Unconfirmed
C*15:02:05	Confirmed	C*15:13	Confirmed	C*15:64	Unconfirmed	C*15:113	Unconfirmed
C*15:02:06	Unconfirmed	C*15:15	Unconfirmed	C*15:65	Unconfirmed	C*15:114	Confirmed
C*15:02:07	Confirmed	C*15:16	Unconfirmed	C*15:66	Unconfirmed	C*15:115N	Unconfirmed
C*15:02:08	Confirmed	C*15:17	Confirmed	C*15:67	Unconfirmed	C*15:116	Unconfirmed
C*15:02:09	Unconfirmed	C*15:18	Confirmed	C*15:68	Unconfirmed	C*15:117	Unconfirmed
C*15:02:10	Unconfirmed	C*15:19	Confirmed	C*15:69	Confirmed	C*15:118	Confirmed
C*15:02:11	Confirmed	C*15:21	Unconfirmed	C*15:70	Unconfirmed	C*15:119	Unconfirmed
C*15:02:12	Unconfirmed	C*15:22	Confirmed	C*15:71	Unconfirmed	C*15:120	Unconfirmed
C*15:02:13	Unconfirmed	C*15:23	Confirmed	C*15:72	Unconfirmed	C*15:121	Unconfirmed
C*15:02:14	Confirmed	C*15:24	Confirmed	C*15:73	Unconfirmed	C*15:122N	Unconfirmed
C*15:02:15	Confirmed	C*15:25	Unconfirmed	C*15:74	Confirmed	C*15:123	Confirmed
C*15:02:16	Unconfirmed	C*15:26	Confirmed	C*15:75	Unconfirmed	C*15:124	Unconfirmed
C*15:02:17	Unconfirmed	C*15:27	Confirmed	C*15:76	Unconfirmed	C*15:125	Unconfirmed
C*15:02:18	Unconfirmed	C*15:28	Confirmed	C*15:77	Unconfirmed	C*15:126	Unconfirmed
C*15:02:19	Unconfirmed	C*15:29	Unconfirmed	C*15:78:01	Unconfirmed	C*15:127	Unconfirmed
C*15:02:20	Confirmed	C*15:30	Confirmed	C*15:78:02	Unconfirmed	C*15:128	Unconfirmed
C*15:02:21	Unconfirmed	C*15:31	Confirmed	C*15:79	Unconfirmed	C*15:129	Unconfirmed
C*15:02:22	Unconfirmed	C*15:32Q	Confirmed	C*15:80	Unconfirmed	C*15:130	Unconfirmed
C*15:02:23	Confirmed	C*15:33	Confirmed	C*15:81	Unconfirmed	C*15:131	Unconfirmed
C*15:02:24	Unconfirmed	C*15:34	Confirmed	C*15:82	Confirmed	C*15:132	Confirmed
C*15:02:25	Unconfirmed	C*15:35	Unconfirmed	C*15:83	Unconfirmed	C*15:133	Unconfirmed
C*15:02:26	Unconfirmed	C*15:36	Confirmed	C*15:84Q	Unconfirmed		
C*15:02:27	Confirmed	C*15:37	Unconfirmed	C*15:85	Confirmed		
C*15:02:28	Unconfirmed	C*15:38	Unconfirmed	C*15:86	Unconfirmed		
C*15:03	Unconfirmed	C*15:39	Confirmed	C*15:87	Unconfirmed		
C*15:04:01	Confirmed	C*15:40	Confirmed	C*15:88	Unconfirmed		
C*15:04:02	Confirmed	C*15:41	Unconfirmed	C*15:89	Unconfirmed		
C*15:05:01	Confirmed	C*15:42	Confirmed	C*15:90	Unconfirmed		
C*15:05:02	Confirmed	C*15:43	Unconfirmed	C*15:91	Unconfirmed		
C*15:05:03	Unconfirmed	C*15:44:01	Confirmed	C*15:92N	Unconfirmed		
C*15:05:04	Unconfirmed	C*15:44:02	Unconfirmed	C*15:93	Unconfirmed		
C*15:05:05	Unconfirmed	C*15:45	Unconfirmed	C*15:94	Unconfirmed		
C*15:05:06	Confirmed	C*15:46	Unconfirmed	C*15:95N	Unconfirmed		
C*15:05:07	Confirmed	C*15:47	Unconfirmed	C*15:96Q	Confirmed		
C*15:05:08	Unconfirmed	C*15:48	Unconfirmed	C*15:97	Unconfirmed		
C*15:05:09	Unconfirmed	C*15:49	Unconfirmed	C*15:98	Unconfirmed		
C*15:05:10	Unconfirmed	C*15:50	Unconfirmed	C*15:99	Unconfirmed		
C*15:05:11	Unconfirmed	C*15:51	Unconfirmed	C*15:100	Unconfirmed		
C*15:05:12	Unconfirmed	C*15:52	Confirmed	C*15:101	Confirmed		
C*15:06:01	Confirmed	C*15:53	Unconfirmed	C*15:102	Confirmed		
C*15:06:02	Confirmed	C*15:54	Unconfirmed	C*15:103	Confirmed		
C*15:06:03	Confirmed	C*15:55	Unconfirmed	C*15:104	Unconfirmed		
C*15:07	Confirmed	C*15:56	Confirmed	C*15:105Q	Unconfirmed		
C*15:08	Unconfirmed	C*15:57	Unconfirmed	C*15:106	Unconfirmed		

<sup>1</sup>Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-October-14, release 3.26.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

**RESOLUTION IN HOMO- AND HETEROZYGOTES**

Results file with resolution in HLA-C\*15 homo- and heterozygotes is available upon request.



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information  
**SPECIFICITY TABLE**

**HLA-C\*15 SSP subtyping**

Specificities and sizes of the PCR products of the 43+1 primer mixes used for  
HLA-C\*15 SSP subtyping

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-C*15 alleles <sup>3</sup>	Other amplified HLA Class I alleles
1	330 bp	800 bp	*15:02:01:01-15:03, 15:05:01:01-15:05:07, 15:05:09-15:13:02, 15:15-15:19, 15:21- 15:24, 15:26-15:29, 15:31-15:39, 15:41- 15:63, 15:67-15:75, 15:78:01-15:101, 15:103-15:104, 15:106- 15:109, 15:111-15:128, 15:130-15:189N, 15:191-15:210, 15:212- 15:221, 15:223- 15:235Q, 15:237- 15:245, 15:247N-15:250	*01:02:22, 01:90, 01:101-01:102, 01:113, 01:116, 02:06:01-02:06:02, 02:23, 02:36:01-02:36:02, 02:68, 03:04:33, 03:04:39, 03:81, 03:175, 03:199, 03:245, 03:317, 03:388, 04:108, 04:178, 04:422, 05:01:58, 05:132, 05:215, 05:238, 06:02:48, 06:89, 06:224, 07:02:137, 07:47:01, 07:123:01- 07:123:02, 07:173, 07:294, 07:626, 07:725, 07:775, 07:850, 08:113, 12:03:57, 12:15, 12:113, 12:208, 12:282, 12:309, 14:92, 16:20, 16:109, 16:169
2	175 bp	1070 bp	*15:02:01:01-15:05:07, 15:05:09-15:09:02, 15:12-15:13:02, 15:15, 15:18-15:19, 15:21- 15:24, 15:26, 15:28- 15:42, 15:44:01-15:62, 15:64-15:106, 15:108- 15:112, 15:114-15:123, 15:125-15:191, 15:193- 15:207, 15:209-15:250	*03:08, 03:29, 03:31, 03:246, 03:555, 07:20:01-07:20:02, 07:96:01-07:96:02, 07:263, 16:70
3 <sup>4</sup>	85 bp 210 bp	1070 bp	*15:28, 15:153 *15:03, 15:16:01- 15:16:02, 15:25 <sup>w</sup>	*03:15, 03:27 <sup>w</sup> , 03:38:01 <sup>w</sup> -03:38:02 <sup>w</sup> , 03:69 <sup>w</sup> , 03:130, 03:136 <sup>w</sup> , 03:163, 03:246 <sup>w</sup> , 03:297, 03:431 <sup>w</sup> , 03:461, 04:16, 04:351:01-04:351:02, 06:03:01, 06:70:02, 06:132:01-06:132:02, 07:02:10 <sup>w</sup> , 07:96:01 <sup>w</sup> -07:96:02 <sup>w</sup> , 07:127:01 <sup>w</sup> , 07:246:01 <sup>w</sup> , 07:263 <sup>w</sup> , 07:314:02 <sup>w</sup> , 07:578 <sup>w</sup> , 07:989 <sup>w</sup> , 12:02:17 <sup>w</sup> , 12:03:23 <sup>w</sup> , 12:140:02 <sup>w</sup> , 12:353
4	315 bp	1070 bp	*15:04:01:01-15:04:06, 15:09:01:01-15:09:02, 15:19, 15:27, 15:30, 15:61, 15:65, 15:77, 15:107, 15:126, 15:143, 15:190, 15:194, 15:211, 15:236	*01:04, 01:21, 01:54, 01:97, 01:102, 01:152, 02:02:01-02:02:03, 02:02:06- 02:05:03, 02:08:01:01-02:18, 02:20- 02:21, 02:24-02:40:02, 02:42-02:46, 02:48-02:67Q, 02:69-02:96, 02:98- 02:110, 02:112-02:157, 02:159-02:196, 02:198-02:212, 03:02:01-03:02:14, 03:02:16-03:02:27, 03:14-03:16, 03:33, 03:36, 03:40:01-03:40:04,



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

	<p>03:42:01-03:43:02, 03:60, 03:71, 03:84, 03:89, 03:95, 03:108, 03:110, 03:119:01-03:119:02, 03:121N, 03:132, 03:139, 03:146, 03:169Q, 03:175, 03:190, 03:194, 03:197-03:201N, 03:216, 03:221-03:222, 03:224N- 03:226, 03:240, 03:245, 03:248, 03:258, 03:264, 03:271, 03:279, 03:298-03:301, 03:315, 03:329-03:330, 03:332, 03:338, 03:349-03:350, 03:361, 03:365, 03:371, 03:373, 03:391N, 03:402-03:403, 03:406, 03:411, 03:425, 03:429, 03:431, 03:449N, 03:452, 03:468, 03:473, 03:475, 03:489, 03:497, 03:505, 03:536, 03:544, 03:547, 03:549, 03:561, 03:575, 03:584, 03:589, 03:596, 04:54:01- 04:54:02, 04:313:01:01-04:313:01:02, 04:360, 04:367, 04:381, 05:04:01- 05:04:02, 05:103:01-05:103:02, 05:135, 05:188, 05:207, 05:215, 06:02:01:01- 06:02:01:92, 06:02:03-06:08, 06:10- 06:33, 06:35-06:37, 06:39-06:102:02, 06:104-06:106:02, 06:108-06:143, 06:145-06:167, 06:169-06:178, 06:180- 06:203, 06:205-06:223, 06:225-06:289, 06:291-06:305, 06:307-06:349, 06:351, 07:01:01:01-07:01:02:14, 07:01:04- 07:01:67, 07:01:69-07:02:62, 07:02:64- 07:03, 07:05-07:10, 07:14-07:27:02, 07:30-07:33N, 07:35-07:40, 07:42- 07:44, 07:46-07:62, 07:64-07:100, 07:102-07:138, 07:140:01-07:141:03, 07:143-07:176, 07:178-07:180, 07:182- 07:183, 07:185-07:198N, 07:200- 07:218, 07:220-07:230, 07:232-07:247, 07:249-07:271, 07:273-07:288, 07:291- 07:294, 07:296-07:322, 07:325-07:327, 07:330:01-07:335, 07:337, 07:339- 07:353, 07:356, 07:359-07:360, 07:362- 07:363, 07:366-07:377, 07:379- 07:393N, 07:396-07:402, 07:404- 07:405:02, 07:407-07:419, 07:421- 07:425, 07:427, 07:429-07:446, 07:448- 07:458, 07:460-07:465, 07:468-07:479, 07:481-07:483N, 07:485-07:486, 07:488-07:500, 07:502-07:521:02, 07:524-07:533, 07:537-07:551N, 07:553-07:561, 07:564-07:568, 07:570- 07:584, 07:587-07:599, 07:601-07:621, 07:623-07:625, 07:627-07:650:02, 07:652-07:654, 07:657-07:663Q, 07:665-07:671, 07:673, 07:675N- 07:692, 07:694-07:697Q, 07:699- 07:724, 07:726N-07:741, 07:743N- 07:750N, 07:752N-07:774, 07:776N- 07:779:01:02, 07:781-07:796N,</p>
--	---





101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

				07:798-07:830, 07:832-07:833N, 07:835-07:837, 07:840N-07:849N, 07:851, 07:853, 07:855-07:856N, 07:859-07:867, 07:869-07:875, 07:877-07:880, 07:882-07:891, 07:893-07:894, 07:898-07:900, 07:902-07:916, 07:918-07:925, 07:927-07:940, 07:942-07:947, 07:949-07:950, 07:952, 07:954N-07:973, 07:975-07:1002, 07:1004-07:1009, 07:1011, 08:09, 08:11, 08:59, 08:113, 08:152, 12:02:01-12:02:14, 12:02:16-12:14:02, 12:16:01-12:30, 12:32-12:140:02, 12:142-12:143, 12:145-12:201, 12:203-12:207, 12:209-12:221, 12:223-12:232N, 12:234, 12:236N-12:281, 12:283-12:297, 12:300-12:308, 12:310-12:327N, 12:329N-12:364, 14:02:01:01-14:25, 14:27-14:53, 14:56-14:78, 14:80-14:91, 14:93N-14:144, 16:01:01:01-16:02:20, 16:04:01:01-16:04:01:03, 16:04:03-16:04:05, 16:06-16:09, 16:11-16:44, 16:46-16:66, 16:68-16:168, 16:170-16:187, 16:189-16:197
<b>5<sup>4,5</sup></b>	100 bp	1070 bp	*15:05:01:01-15:05:07, 15:05:09-15:05:18, 15:22-15:23:02, 15:29, 15:36, 15:46, 15:54, 15:59, 15:69-15:70, 15:90, 15:104, 15:108, 15:110-15:111, 15:115N-15:117, 15:125, 15:140, 15:147-15:148, 15:152:01-15:153, 15:164N-15:165, 15:167, 15:169, 15:181, 15:185N, 15:201, 15:204, 15:208, 15:218, 15:224, 15:229, 15:233-15:235Q, 15:244	*04:108, 07:626, 12:309, 16:169, <b>B*07:246, B*35:03:11, B*35:205:01</b>
	160 bp		*15:92N	
<b>6</b>	305 bp	1070 bp	*15:06:01-15:06:03, 15:40, 15:55, 15:158, 15:177N, 15:180, 15:214	
	345 bp		*15:26, 15:69, 15:194	
	370 bp		*15:22, 15:37, 15:55, 15:58, 15:65, 15:72, 15:125, 15:190, 15:246	
<b>7</b>	140 bp	<b>800 bp</b>	*15:07:01:01-15:07:01:02, 15:21, 15:25, 15:116, 15:144	*01:02:34, 01:21, 02:12, 02:27:01-02:27:02, 02:87, 02:115, 02:126, 02:131, 03:03:64, 03:04:25, 04:11, 04:29, 04:36, 04:55, 04:172, 04:214, 04:449, 04:473, 07:01:74, 07:02:09, 07:125:02, 07:583, 07:723, 08:01:01:01-08:01:07, 08:01:09-08:01:29,



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

				08:01:31-08:02:10, 08:02:12-08:09, 08:11-08:63, 08:65-08:94, 08:95 <sup>w</sup> , 08:96-08:243, 12:02:01-12:02:10, 12:02:12-12:02:22, 12:02:23 <sup>w</sup> , 12:02:24-12:02:27, 12:02:28 <sup>w</sup> , 12:02:30-12:03:03, 12:03:05-12:03:08, 12:03:10-12:03:23, 12:03:24 <sup>w</sup> , 12:03:25-12:03:33, 12:03:35-12:03:69, 12:03:70 <sup>w</sup> , 12:03:71-12:03:78, 12:06-12:08, 12:10:01-12:16:01, 12:17-12:20, 12:22-12:26, 12:28-12:32, 12:34-12:40, 12:42Q-12:53, 12:55-12:59, 12:61-12:122, 12:124-12:145, 12:147-12:187, 12:189-12:194, 12:195:02, 12:196-12:298, 12:300-12:352, 12:354-12:357, 12:359-12:361, 12:363-12:364, 14:02:03, 14:03:01:01-14:03:01:03, 14:03:03-14:03:05, 14:08, 14:10, 14:22, 14:35N, 14:38, 14:41, 14:53-14:54, 14:61, 14:70, 14:79, 14:86, 14:90, 14:112-14:113, 14:116, 14:118, 14:126, 14:141N, 16:01:01:01-16:01:01:37, 16:01:03-16:01:15, 16:01:17-16:01:25, 16:01:27-16:01:42, 16:04:01:01-16:04:01:03, 16:04:03-16:04:05, 16:06-16:08, 16:10-16:11, 16:13-16:18, 16:20-16:24, 16:26-16:45, 16:49:01-16:56, 16:58-16:59, 16:61-16:62, 16:64-16:68, 16:71 <sup>w</sup> , 16:72-16:73, 16:75-16:76, 16:78-16:83, 16:86-16:87, 16:92-16:93, 16:95-16:98, 16:100, 16:105, 16:109-16:114, 16:116-16:119, 16:122, 16:124-16:125, 16:127-16:131, 16:134-16:135, 16:137-16:139, 16:141-16:142, 16:146-16:152, 16:154, 16:157-16:162, 16:164-16:165, 16:168-16:169, 16:170 <sup>w</sup> , 16:171-16:175, 16:177-16:178, 16:180, 16:182-16:183, 16:185-16:188, 16:190, 16:192-16:193, 16:196-16:197, <b>B*07:02:77, B*08:01:36, B*15:01:50, B*15:436, B*18:03:02, B*35:08:02, B*35:08:05, B*55:01:25, B*67:02:01:01-67:02:01:02</b>
8	160 bp	1070 bp	*15:08:01-15:08:02, 15:74	*01:90 <sup>w</sup> , 01:136, 02:06:01-02:06:02, 02:47, 05:132, 06:168, 06:224, 12:15, 12:208, <b>B*07:78<sup>w</sup>, B*07:424, B*13:18<sup>w</sup>, B*13:31<sup>w</sup>, B*13:41<sup>w</sup>, B*13:73<sup>w</sup>, B*13:128<sup>w</sup>, B*13:131<sup>w</sup>, B*13:145<sup>w</sup>, B*13:164<sup>w</sup>, B*15:73:01:01<sup>w</sup>-15:73:01:02<sup>w</sup>, B*15:303<sup>w</sup>, B*15:486<sup>w</sup>, B*54:10<sup>w</sup>, B*54:20<sup>w</sup>, B*54:33<sup>w</sup>, B*54:40<sup>w</sup>, B*55:09<sup>w</sup>, B*55:21<sup>w</sup>, B*55:37<sup>w</sup>, B*55:52<sup>w</sup>, B*56:43<sup>w</sup>, B*56:51<sup>w</sup>, B*56:63<sup>w</sup></b>
	185 bp		*15:19	



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

Lot No.	Allele	Length	Allele	Length	Allele	Length
9	135 bp	1070 bp	*15:11, 15:23:01-15:23:02, 15:63, 15:118, 15:138, 15:158		*02:02:01-02:02:03, 02:02:06-02:02:12, 02:02:14-02:02:25, 02:02:27-02:02:28, 02:02:30-02:20, 02:22-02:25Q, 02:27:01-02:38:02N, 02:40:01-02:40:02, 02:42-02:44, 02:46-02:86, 02:88-02:100, 02:101 <sup>w</sup> , 02:102-02:133, 02:135N-02:151, 02:153-02:166, 02:168-02:188, 02:190, 02:192N-02:212, 04:03:01:01-04:03:08, 04:06:01-04:06:03, 04:42:01-04:42:02, 04:80, 04:107, 04:147, 04:160:01-04:160:02, 04:171, 04:190, 04:220, 04:256, 04:286, 04:294, 04:299, 04:335, 04:337, 04:357, 04:363, 04:381, 04:383, 04:393, 04:400, 04:402, 04:473, 05:26, 05:43, 06:02:72, 06:05, 07:01:74, 07:02:09, 07:125:02, 08:37, 12:16:01, 12:147, 12:195:02, 12:217, 16:21, 16:34, 16:80, 16:121	
			*04:210, 04:237, 05:182			
10	305 bp	1070 bp	*15:18		*01:64, 01:168, 02:08:01:01-02:08:01:02, 02:87, 02:134, 02:189, 03:18:01-03:18:03, 03:64:01-03:64:02, 03:231, 03:301, 03:530, 03:557, 04:01:01:01-04:01:01:29, 04:01:01:31-04:01:02, 04:01:04-04:01:137, 04:01:139-04:01:144, 04:04:01:01-04:05, 04:07:01-04:15:03, 04:17-04:20, 04:23-04:79, 04:81-04:106, 04:108-04:132, 04:134-04:139, 04:141-04:146, 04:148-04:159, 04:161-04:165, 04:167-04:170N, 04:172-04:189, 04:191N-04:219, 04:221-04:255N, 04:257-04:285, 04:287-04:293, 04:295-04:298, 04:300N-04:334, 04:336, 04:338Q-04:350N, 04:352-04:356, 04:358-04:362N, 04:364N-04:380, 04:382Q, 04:384-04:392, 04:394-04:399, 04:401, 04:403-04:458, 04:460-04:472, 04:474-04:475, 05:01:01:01-05:01:21, 05:01:23-05:01:49, 05:01:51-05:01:69, 05:03-05:57, 05:59-05:97, 05:99N-05:126, 05:128N-05:196, 05:198-05:204, 05:206-05:244N, 05:246-05:272, 06:28, 06:76:01-06:76:02, 07:64, 07:73:01-07:73:02, 07:92, 07:172:01-07:172:02, 07:583, 07:723, 07:884, 07:891, 08:01:01:01-08:01:07, 08:01:09-08:13, 08:15:01-08:57, 08:59-08:63, 08:65-08:79, 08:81-08:102, 08:104, 08:106-08:133, 08:135-08:154, 08:156-08:238, 08:240-08:243, 12:02:01-12:02:37, 12:02:39-12:03:49, 12:03:51-12:15, 12:17-12:70, 12:72-12:139Q, 12:141-12:146, 12:148N-12:226, 12:228-12:238, 12:240-12:278, 12:280-12:298,	
	170 bp		*15:10:01-15:10:04, 15:107, 15:208			



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

				12:300-12:352, 12:354-12:364, 14:02:01:01-14:02:09, 14:02:11- 14:02:40, 14:04-14:09, 14:11-14:17, 14:19-14:21N, 14:23-14:34, 14:36- 14:37, 14:39-14:40, 14:42-14:52, 14:55- 14:60, 14:62-14:69, 14:71-14:78, 14:80- 14:84, 14:87, 14:89, 14:91-14:111, 14:114-14:115, 14:117N, 14:119- 14:125, 14:127-14:140, 14:142-14:144, 16:01:01:01-16:02:20, 16:04:01:01- 16:04:01:03, 16:04:03-16:04:05, 16:06- 16:33, 16:35-16:69, 16:71-16:79, 16:81- 16:84, 16:86-16:120, 16:122-16:133, 16:135-16:197, 17:01:01:02-17:01:07, 17:01:09-17:03:02, 17:04-17:40, 17:42- 17:59, 17:61-17:63, 18:04
11	315 bp	800 bp	*15:02:01:01-15:03, 15:07:01:01-15:08:02, 15:10:01-15:13:02, 15:15-15:18, 15:21, 15:26, 15:28, 15:31- 15:35, 15:37-15:39, 15:41-15:45, 15:47- 15:53, 15:56-15:58, 15:60, 15:62-15:63, 15:67-15:68, 15:71- 15:75, 15:78:01-15:89, 15:91-15:101, 15:103, 15:106, 15:109, 15:112- 15:114, 15:118-15:124, 15:127, 15:129-15:139, 15:141, 15:144-15:146, 15:149-15:151, 15:154- 15:157, 15:159-15:163, 15:166, 15:168, 15:170- 15:176, 15:178-15:179, 15:182-15:184, 15:186- 15:189N, 15:191- 15:193, 15:195-15:200, 15:202-15:203, 15:205- 15:207, 15:209-15:210, 15:212-15:213N, 15:215-15:217, 15:219- 15:221, 15:223, 15:225- 15:228, 15:230-15:232, 15:237-15:243, 15:245, 15:248-15:250	*01:136, 02:06:01-02:06:02, 02:47, 03:19, 03:102, 03:307, 04:178, 05:132, 06:168, 06:224, 07:289, 07:725, 12:15, 12:208
12 <sup>4</sup>	100 bp 200 bp 240 bp	1070 bp	*15:28, 15:153 *15:95N *15:07:01:01- 15:07:01:02, 15:21, 15:25, 15:43, 15:116, 15:144	*01:169:02, 02:12, 02:27:01-02:27:02, 02:115, 02:126, 02:131, 03:02:01- 03:02:09, 03:02:11-03:03:14, 03:03:15 <sup>w</sup> , 03:03:16-03:03:20, 03:03:22-03:03:50, 03:03:52-03:03:54, 03:03:55 <sup>w</sup> , 03:03:56- 03:04:16, 03:04:18-03:04:25, 03:04:27- 03:04:68, 03:04:70-03:04:76, 03:04:77 <sup>w</sup> ,



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

				03:04:78-03:04:84, 03:04:86-03:06:02, 03:08-03:11:02, 03:13:01:01-03:14, 03:16-03:17:02, 03:18:02-03:38:02, 03:40:01-03:44, 03:46-03:64:01, 03:65-03:66, 03:68-03:98, 03:100-03:114, 03:116:01-03:129, 03:131-03:133, 03:135-03:136, 03:138-03:139, 03:141-03:143, 03:145-03:155, 03:157-03:162, 03:164-03:165:02, 03:167-03:169Q, 03:171-03:181, 03:183-03:194, 03:196-03:230, 03:232-03:242, 03:244Q-03:246, 03:248-03:263:03, 03:265N-03:267, 03:269-03:277N, 03:278 <sup>w</sup> , 03:279-03:294, 03:295 <sup>w</sup> , 03:296:01-03:296:02, 03:298-03:343, 03:345-03:376, 03:378-03:453, 03:455-03:456, 03:458, 03:460, 03:462N-03:503, 03:505-03:529, 03:531N-03:549, 03:551-03:556, 03:558-03:565, 03:566 <sup>w</sup> , 03:567-03:596, 04:473, 07:96:01-07:96:02, 07:314:02, 07:578, 07:756, 12:02:17, 12:03:23, 12:140:02, 16:34, <b>B*15:01:72, B*15:125:02, B*40:164, B*46:01:33, B*46:77</b>
<b>13<sup>4</sup></b>	125 bp 185 bp	1070 bp	*15:24 *15:12, 15:144	*01:116, 04:89, 04:135, 05:47, 14:92 *03:03:64, 04:52, 04:55, 04:405, 05:55, 12:58, 12:252, 14:10
<b>14</b>	130 bp  440 bp	<b>800 bp</b>	*15:13:01:01-15:13:02, 15:103, 15:172 *15:11, 15:16:01-15:17, 15:43	*04:451  *01:90, 01:136, 01:145:01N, 02:06:01-02:06:02, 02:47, 03:19, 03:102, 03:307, 03:318N, 04:178, 05:132, 06:168, 06:224, 07:289, 08:207, 12:03:66, 12:15, 12:208, <b>B*46:11, B*46:18, B*56:08, B*56:14</b>
<b>15<sup>4</sup></b>	85 bp	1070 bp	*15:02:01:01-15:05:07, 15:05:09-15:06:03, 15:08:01-15:10:04, 15:12-15:13:02, 15:15, 15:18-15:19, 15:21-15:24, 15:26, 15:28-15:42, 15:44:01-15:47, 15:49-15:84Q, 15:86-15:94, 15:96Q-15:143, 15:145N-15:155, 15:157-15:180, 15:182-15:250	*03:29, 04:112, 04:169, 05:36, 06:44, 07:07, 07:09, 07:559, 07:914, 16:70, 18:05
<b>16<sup>4</sup></b>	90 bp 165 bp 345 bp	1070 bp	*15:27 *15:15, 15:77, 15:195 *15:26, 15:69, 15:194	<b>B*35:222, B*35:525, B*42:22</b>
<b>17<sup>6</sup></b>	140 bp 215 bp 295 bp	1070 bp	*15:34 *15:36 *15:39, 15:130, 15:195	*06:320, 14:81 *04:112, 04:169, 14:73 *01:30, 02:142, 05:216:01:01-05:216:01:02, 06:207, 08:51, 08:114, 08:243, 12:87, 14:76



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

<b>18<sup>6</sup></b>	215 bp	1070 bp	*15:31	*03:14, 03:162, 03:230, 03:234, 03:261, 03:309, 03:325, 03:361, 07:10, 07:43:01-07:43:02, 07:184, 07:196, 07:367, 07:568, 08:44, 08:61, 08:82, 08:209, <b>B*15:88, B*44:247, B*44:295:01-44:295:02, B*58:05</b>
<b>19</b>	165 bp 355 bp	1070 bp	*15:42, 15:111, 15:201 *15:46, 15:172	
<b>20<sup>4</sup></b>	120 bp 200 bp 235 bp 295 bp	1070 bp	*15:44:01-15:44:02 *15:95N *15:45 *15:97	*03:148  *02:200, 03:492, 03:497, 04:146, 06:349, 07:708, 12:254, 12:280
<b>21</b>	165 bp 445 bp	<b>800 bp</b>	*15:47, 15:92N *15:35	*02:35, 02:120, 04:238, 05:21, 06:223
<b>22</b>	225 bp 295 bp	<b>800 bp</b>	*15:38 *15:97	*02:200, 03:492, 03:497, 04:146, 06:349, 07:708, 12:254, 12:280
<b>23<sup>5</sup></b>	175 bp 545 bp	1070 bp	*15:48 *15:29, 15:87	*01:85, 02:178, 03:357, 03:376, 03:452, 04:277, 05:212, 06:266, 08:22:01:01-08:22:01:02, 08:56, 08:154, 08:178, 08:202, 12:290, 12:304, 16:133
<b>24</b>	175 bp 330 bp 380 bp	1070 bp	*15:32Q *15:105Q *15:41	*06:74Q
<b>25<sup>4</sup></b>	125 bp 225 bp	1070 bp	*15:122N *15:52:01-15:52:02	<b>B*08:293N, B*39:95N, B*52:96N B*15:363:01-15:363:02, B*18:91, B*35:247:01-35:247:02, B*35:510, B*39:122, B*51:188, B*58:45:01-58:45:02</b>
<b>26</b>	200 bp	1070 bp	*15:56, 15:103, 15:127	<b>B*15:193, B*35:132, B*35:246, B*35:283, B*38:164, B*39:53, B*39:57, B*40:171, B*51:95</b>
<b>27<sup>6</sup></b>	330 bp	1070 bp	*15:30, 15:105Q	*02:148, 04:463, 07:174, 07:298, 08:112, 12:165
<b>28<sup>4</sup></b>	375 bp 85 bp 180 bp	1070 bp	*15:123 *15:33 *15:84Q	<b>B*57:97</b>
<b>29<sup>4</sup></b>	120 bp 255 bp	1070 bp	*15:96Q *15:81	*04:59Q, 04:428Q, 16:16Q, <b>B*15:218Q</b>
<b>30<sup>4</sup></b>	90 bp	1070 bp	*15:82	
<b>31</b>	150 bp	1070 bp	*15:07:01:01-15:07:01:02, 15:25, 15:85, 15:144, 15:181	*01:02:34, 01:21, 02:27:01-02:27:02, 02:65, 02:87, 02:115, 02:131, 03:03:64, 03:04:25, 04:11, 04:29, 04:36, 04:55, 04:114, 04:172, 04:383, 04:473, 05:20, 07:01:74, 07:02:09, 07:125:02, 07:583, 07:723, 08:01:01:01-08:01:07, 08:01:09-08:01:29, 08:01:31-08:02:10, 08:02:12-08:09, 08:11-08:63, 08:65-08:94, 08:95 <sup>w</sup> , 08:96-08:145, 08:147-08:243, 12:02:01-12:02:10, 12:02:12-12:02:22, 12:02:24-12:02:27, 12:02:28 <sup>w</sup> , 12:02:30-12:03:03, 12:03:05-12:03:08, 12:03:10-12:03:23, 12:03:24 <sup>w</sup> , 12:03:25-12:03:33,



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

				12:03:35-12:03:69, 12:03:71-12:03:78, 12:06-12:08, 12:10:01-12:16:01, 12:17-12:20, 12:22-12:32, 12:34-12:40, 12:42Q-12:59, 12:61-12:68, 12:70-12:71, 12:73-12:122, 12:124-12:134, 12:136-12:145, 12:147-12:153, 12:155Q-12:194, 12:195:02, 12:196-12:298, 12:300-12:352, 12:354-12:364, 14:02:03, 14:03:01:01-14:03:01:03, 14:03:03-14:03:05, 14:08, 14:10, 14:22, 14:35N, 14:38, 14:41, 14:53-14:54, 14:61, 14:70, 14:79, 14:86, 14:90, 14:112-14:113, 14:116, 14:118, 14:126, 14:141N, 16:01:01:01-16:01:01:37, 16:01:03-16:01:15, 16:01:17-16:01:42, 16:04:01:01-16:04:01:03, 16:04:03-16:04:05, 16:06-16:08, 16:10-16:11, 16:13-16:18, 16:20-16:24, 16:26-16:36, 16:38-16:45, 16:49:01-16:59, 16:61-16:62, 16:64-16:68, 16:71 <sup>w</sup> , 16:72-16:73, 16:75-16:76, 16:78-16:83, 16:86-16:87, 16:92-16:93, 16:95-16:98, 16:100, 16:105-16:106, 16:109-16:114, 16:116-16:119, 16:122, 16:124-16:125, 16:127-16:131, 16:134-16:135, 16:137-16:139, 16:141-16:142, 16:146-16:152, 16:154, 16:157-16:162, 16:164-16:165, 16:168-16:169, 16:170 <sup>w</sup> , 16:171-16:175, 16:177-16:178, 16:180, 16:182-16:183, 16:185-16:190, 16:192-16:193, 16:196-16:197, <b>B*07:02:77, B*08:01:36, B*15:01:50, B*15:436, B*18:03:02, B*35:08:02, B*35:08:05, B*55:01:25, B*67:02:01:01-67:02:01:02</b>
<b>32</b>	160 bp	1070 bp	*15:74	*02:06:01-02:06:02, 02:47, 06:168, 06:224, 12:15, 12:208
<b>33<sup>4</sup></b>	75 bp	1070 bp	*15:02:01:01-15:05:07, 15:05:09-15:05:10, 15:05:13-15:06:03, 15:08:01-15:10:04, 15:12-15:13:02, 15:15, 15:18-15:19, 15:22-15:24, 15:26, 15:28-15:42, 15:44:01-15:47, 15:49-15:70, 15:72-15:94, 15:96Q-15:115N, 15:117-15:143, 15:145N-15:155, 15:157-15:243, 15:245-15:247N, 15:249-15:250	*01:118, 04:112, 04:169, 05:36, 06:44, 07:07, 07:09, 07:210, 07:247, 12:188, 16:70, 18:05
<b>34<sup>4</sup></b>	110 bp 140 bp	1070 bp	*15:108 *15:114	*03:505
<b>35<sup>4</sup></b>	120 bp	1070 bp	*15:115N	*04:205N, 06:128N
<b>36</b>	210 bp	1070 bp	*15:102	*01:02:01:01-01:02:31, 01:02:33-01:02:77, 01:02:79-01:03:03,





101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

				01:06-01:07:01, 01:08, 01:10-01:11, 01:13-01:20, 01:23-01:33, 01:38-01:48, 01:51-01:54, 01:56N-01:76, 01:78, 01:80-01:90, 01:92-01:96, 01:98N-01:100, 01:103-01:113, 01:115-01:119, 01:121Q-01:130, 01:132-01:157, 01:159, 01:161-01:175, 01:177-01:192, 01:194-01:204, 01:206-01:211N, 01:213-01:214, 01:216-01:225, 01:227-01:230, 03:58, 03:86, 03:94, 04:37, 05:85, 05:107, 05:241, 06:204, 14:45
<b>37<sup>4</sup></b>	125 bp 220 bp	1070 bp	*15:122N *15:101	<b>B*08:293N, B*39:95N, B*52:96N B*40:270</b>
<b>38</b>	360 bp	1070 bp	*15:124	
<b>39<sup>4</sup></b>	110 bp 155 bp	1070 bp	*15:108 *15:132	*03:505
<b>40</b>	320 bp	<b>800 bp</b>	*15:02:01:08N	
<b>41</b>	220 bp	1070 bp	*15:145N	<b>B*08:82N</b>
<b>42</b>	195 bp	1070 bp	*15:57, 15:117	
<b>43</b>	365 bp	1070 bp	*15:22, 15:65, 15:72, 15:190, 15:246	
<b>44<sup>7</sup></b>	-	-	<b>Negative Control</b>	

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of C\*15 high resolution SSP typings. When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers. PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1<sup>st</sup> and/or 4<sup>th</sup> exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances, it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

<sup>4</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>5</sup>Primer mixes 5 and 23 may give rise to a lower yield of HLA-specific PCR product than the other C\*15 primer mixes.

<sup>6</sup>Primer mixes 17, 18 and 27 may have tendencies of unspecific amplifications.





101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

**Lot No.: 0R9**

**Lot-specific information**

<sup>7</sup>Primer mix 44 contains a negative control, which will amplify the majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

Abbreviations

w: might be weakly amplified.



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information  
**PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec. PCR product	330	175	85	315	100	305	140	160	135	170	315	100
			210		160	345		185	305			200
						370						240
Length of int. pos. control <sup>1</sup>	800	1070	1070	1070	1070	1070	800	1070	1070	1070	800	1070
5'-primer(s) <sup>2</sup>	399	134	118	419	358	355	201	125	97	1 <sup>st</sup>	420	105
	5'-CTg <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-gTC <sup>3'</sup>	5'-TCT <sup>3'</sup>	5'-CCC <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CgA <sup>3'</sup>	5'-TCg <sup>3'</sup>	5'-CgA <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-gCT <sup>3'</sup>
	408				420	379		420	118		420	
	5'-ggA <sup>3'</sup>				5'-TTC <sup>3'</sup>	5'-ACg <sup>3'</sup>		5'-TTA <sup>3'</sup>	5'-CCA <sup>3'</sup>		5'-TTA <sup>3'</sup>	
	409					419			430			
	5'-ggC <sup>3'</sup>					5'-gTA <sup>3'</sup>			5'-ACC <sup>3'</sup>			
3'-primer(s) <sup>3</sup>	3 <sup>rd</sup>	270	164	3 <sup>rd</sup>	477	3 <sup>rd</sup>	302	270	201	134	3 <sup>rd</sup>	164
	5'-CTC <sup>3'</sup>	5'-TAG <sup>3'</sup>	5'-gCA <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-gCg <sup>3'</sup>	5'-ggA <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-TAG <sup>3'</sup>	5'-CTT <sup>3'</sup>	5'-AgC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-gCA <sup>3'</sup>
			289				302	539	3 <sup>rd</sup>			265
			5'-AgC <sup>3'</sup>				5'-ggC <sup>3'</sup>	5'-TCC <sup>3'</sup>	5'-CTC <sup>3'</sup>			5'-CTA <sup>3'</sup>
												302
												5'-ggC <sup>3'</sup>
												302
												5'-ggC <sup>3'</sup>
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec. PCR product	125	130	85	90	140	215	165	120	165	225	175	175
	185	440		165	215		355	200	445	295	545	330
				345	295			235				380
								295				
Length of int. pos. control <sup>1</sup>	1070	800	1070	1070	1070	1070	1070	1070	800	800	1070	1070
5'-primer(s) <sup>2</sup>	201	270	270	261	98	355	368	105	322	128	134	356
	5'-CCA <sup>3'</sup>	5'-AAg <sup>3'</sup>	5'-AAC <sup>3'</sup>	5'-AAC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-TCA <sup>3'</sup>	5'-gTC <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-gCC <sup>3'</sup>	5'-AgT <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CAA <sup>3'</sup>
	2 <sup>nd</sup>	757		379	2 <sup>nd</sup>		560	3 <sup>rd</sup>	358	3 <sup>rd</sup>	972	404
	5'-CCA <sup>3'</sup>	5'-CCC <sup>3'</sup>		5'-ACg <sup>3'</sup>	5'-CCA <sup>3'</sup>		5'-CgA <sup>3'</sup>	5'-Cgg <sup>3'</sup>	5'-TCT <sup>3'</sup>	5'-Cgg <sup>3'</sup>	5'-CTA <sup>3'</sup>	5'-CCg <sup>3'</sup>
				560					715			562
				5'-CCT <sup>3'</sup>					5'-CAg <sup>3'</sup>			5'-Cgg <sup>3'</sup>
3'-primer(s) <sup>3</sup>	343	420	312	312	270	527	3 <sup>rd</sup>	186	477	312	266	3 <sup>rd</sup>
	5'-T <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-AgT <sup>3'</sup>	5'-AgT <sup>3'</sup>	5'-TAG <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-ggA <sup>3'</sup>	5'-TCC <sup>3'</sup>	5'-gCg <sup>3'</sup>	5'-AgT <sup>3'</sup>	5'-TCA <sup>3'</sup>	5'-CTC <sup>3'</sup>
	412	846		3 <sup>rd</sup>	427			186	846	845	1034	
	5'-gTT <sup>3'</sup>	5'-CAC <sup>3'</sup>		5'-ggA <sup>3'</sup>	5'-gTT <sup>3'</sup>			5'-TCT <sup>3'</sup>	5'-CAC <sup>3'</sup>	5'-ACA <sup>3'</sup>	5'-AgT <sup>3'</sup>	
					583			265				
					5'-gTg <sup>3'</sup>			5'-CTA <sup>3'</sup>				
								299				
								5'-TCT <sup>3'</sup>				
								845				
								5'-ACA <sup>3'</sup>				
Well No.	13	14	15	16	17	18	19	20	21	22	23	24



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **OR9**

Lot-specific information

Well No.	25	26	27	28	29	30	31	32	33	34	35	36
Length of spec.	125	200	330	85	120	90	150	160	75	110	120	210
PCR product	225		375	180	255					140		
Length of int.	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	409	409	363	409	486	797	201	420	270	105	232	368
	5'-ggC 3'	5'-ggC 3'	5'-AgT 3'	5'-ggC 3'	5'-ACg 3'	5'-CCg 3'	5'-CCA 3'	5'-TTA 3'	5'-AAC 3'	5'-gCT 3'	5'-AgT 3'	5'-gTg 3'
			404		631							
			5'-CCg 3'		5'-Agg 3'							
			404									
			5'-CCA 3'									
3'-primer(s) <sup>3</sup>	493	565	3 <sup>rd</sup> I	455	563	846	312	538	302	172	312	538
	5'-CTA 3'	5'-CAT 3'	5'-CTC 3'	5'-CCA 3'	5'-CgT 3'	5'-CAC 3'	5'-Agg 3'	5'-CCA 3'	5'-ggT 3'	5'-CAT 3'	5'-AgT 3'	5'-CCg 3'
	595	575		549	846					205		
	5'-CCg 3'	5'-ggg 3'		5'-..g 3'	5'-CAC 3'					5'-CCT 3'		
	595											
	5'-CCT 3'											
Well No.	25	26	27	28	29	30	31	32	33	34	35	36

Well No.	37	38	39	40	41	42	43
Length of spec.	125	360	110	320	220	195	365
PCR product	220		155				
Length of int.	1070	1070	1070	800	1070	1070	1070
pos. control <sup>1</sup>							
5'-primer(s) <sup>2</sup>	409	283	105	312	409	527	361
	5'-ggC 3'	5'-AgA 3'	5'-gCT 3'	5'-AAA 3'	5'-ggC 3'	5'-TgT 3'	5'-AgA 3'
3'-primer(s) <sup>3</sup>	493	353	172	3 <sup>rd</sup> I	589	3 <sup>rd</sup> I	3 <sup>rd</sup> I
	5'-CTA 3'	5'-TgA 3'	5'-CAT 3'	5'-ggC 3'	5'-CTA 3'	5'-ggA 3'	5'-ggA 3'
	589		221				
	5'-CTg 3'		5'-ACT 3'				
Well No.	37	38	39	40	41	42	43

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information

CELL LINE VALIDATION SHEET																			
HLA-C*15 SSP primer set <sup>2</sup>																			
				Well															
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
				202015701	202015702	202015703	202015704	202015705	202015706	202015707	202015708	202015709	202015710	202015711	202015712	202015713	202015714	202015715	202015716
			Prod. No.:																
	IHWC cell line <sup>1</sup>		C*																
1	9001 SA		*07:02		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*07:01	*15:05	+	+	-	+	+	-	-	-	-	-	-	-	-	+	-
3	9011 E4181324		*12:02		-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
4	9275 GU373		*03:04	*04:01	-	-	-	-	-	-	-	-	+	-	+	-	-	-	-
5	9009 KAS011		*06:02		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*03:04	*07:02	-	-	-	+	-	-	-	-	-	-	+	-	-	-	-
7	9020 QBL		*05:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
8	9025 DEU		*04:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
9	9026 YAR		*12:03		-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
10	9107 LKT3		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT		*16:01		-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
12	9052 DBB		*06:02		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA		*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
15	9075 DKB		*03:04		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
16	9037 SWEIG007		*02:02		-	-	-	+	-	-	-	-	+	-	-	-	-	-	-
17	9282 CTM3953540		*03:03	*07:01	-	-	-	+	-	-	-	-	-	-	+	-	-	-	-
18	9257 32367		*01:02	*07:05	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16		*07:01		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005		*03:04		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
21	9064 AMALA		*03:03		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
22	9056 KOSE		*12:03		-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
23	9124 IHL		*01:02	*15:02	+	+	-	-	-	-	-	-	-	+	-	-	-	+	-
24	9035 JBUSH		*12:03		-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
25	9049 IBW9		*08:02		-	-	-	-	-	-	+	-	+	-	-	-	-	-	-
26	9285 WT49		*07:18		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007		*07:04	*15:29	+	+	-	-	+	-	-	-	-	-	-	-	-	+	-
28	9320 BEL5GB		*05:01	*16:01	-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
29	9050 MOU		*16:01		-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
30	9021 RSH		*17:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
31	9019 DUCAF		*05:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
32	9297 HAG		*17:03		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
33	9098 MT14B		*03:04		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
34	9104 DHIF		*12:03		-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
35	9302 SSTO		*05:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
36	9024 KT17		*03:03	*04:01	-	-	-	-	-	-	-	-	+	-	+	-	-	-	-
37	9065 HHKB		*07:02		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*03:03		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
39	9315 CML		*02:02	*07:01	-	-	-	+	-	-	-	+	+	-	-	-	-	-	-
40	9134 WHONP199		*01:02	*06:02	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301		*08:02		-	-	-	-	-	-	+	-	+	-	-	-	-	-	-
42	9066 TAB089		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526		*01:02	*08:01	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-
44	9057 TEM		*12:03		-	-	-	+	-	-	+	-	+	-	-	-	-	-	-
45	9239 SHJO		*06:02	*17:01	-	-	-	+	-	-	-	-	+	-	-	-	-	-	-
46	9013 SCHU		*07:02		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*07:04	*15:02	+	+	-	-	-	-	-	-	-	+	-	-	-	+	-
48	9303 TER-ND		*04:01	*16:01	-	-	-	+	-	-	+	-	+	-	-	-	-	-	-



101.626-12 – including Taq polymerase  
101.626-12u – without Taq polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-C*15 SSP primer set <sup>2</sup>																				
				Well																
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	
				Prod. No.:	202015717	202015718	202015719	202015720	202015721	202015722	202015723	202015724	202241725	202015726	202015727	202015728	202015729	202015730	202015731	202015732
	IHCW cell line <sup>1</sup>		C*																	
1	9001 SA		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*07:01	*15:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324		*12:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373		*03:04	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
5	9009 KAS011		*06:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL		*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU		*04:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT		*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
12	9052 DBB		*06:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA		*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007		*02:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540		*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367		*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16		*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA		*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
23	9124 IHL		*01:02	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
25	9049 IBW9		*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
26	9285 WT49		*07:18		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007		*07:04	*15:29	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB		*05:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
29	9050 MOU		*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
30	9021 RSH		*17:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF		*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG		*17:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
35	9302 SSTO		*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17		*03:03	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML		*02:02	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199		*01:02	*06:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301		*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
42	9066 TAB089		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526		*01:02	*08:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
44	9057 TEM		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
45	9239 SHJO		*06:02	*17:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*07:04	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND		*04:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information

CELL LINE VALIDATION SHEET															
HLA-C*15 SSP primer set <sup>2</sup>															
				Well											
				33	34	35	36	37	38	39	40	41	42	43	
				Prod. No.:	202015733	202015734	202015735	202015736	202015737	202015740	202015739	202015740	202015741	202241742	201241744
	IHWC cell line <sup>1</sup>		C*												
1	9001 SA		*07:02	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*07:01	*15:05	+	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324		*12:02		-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373		*03:04	*04:01	-	-	-	-	-	-	-	-	-	-	-
5	9009 KAS011		*06:02		-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL		*05:01		-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU		*04:01		-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR		*12:03		-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3		*01:02		-	-	-	+	-	-	-	-	-	-	-
11	9051 PITOUT		*16:01		-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB		*06:02		-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM		*01:02		-	-	-	+	-	-	-	-	-	-	-
14	9071 OLGA		*01:02	*03:04	-	-	-	+	-	-	-	-	-	-	-
15	9075 DKB		*03:04		-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007		*02:02		-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540		*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367		*01:02	*07:05	-	-	-	+	-	-	-	-	-	-	-
19	9038 BM16		*07:01		-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005		*03:04		-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA		*03:03		-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE		*12:03		-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL		*01:02	*15:02	+	-	-	+	-	-	-	-	-	-	-
24	9035 JBUSH		*12:03		-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9		*08:02		-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49		*07:18		-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007		*07:04	*15:29	+	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB		*05:01	*16:01	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU		*16:01		-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH		*17:01		-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF		*05:01		-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG		*17:03		-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B		*03:04		-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF		*12:03		-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO		*05:01		-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17		*03:03	*04:01	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB		*07:02		-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*03:03		-	-	-	-	-	-	-	-	-	-	-
39	9315 CML		*02:02	*07:01	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199		*01:02	*06:02	-	-	-	+	-	-	-	-	-	-	-
41	9055 H0301		*08:02		-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089		*01:02		-	-	-	+	-	-	-	-	-	-	-
43	9076 T7526		*01:02	*08:01	-	-	-	+	-	-	-	-	-	-	-
44	9057 TEM		*12:03		-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO		*06:02	*17:01	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU		*07:02		-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*07:04	*15:02	+	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND		*04:01	*16:01	-	-	-	-	-	-	-	-	-	-	-



**101.626-12 – including *Taq* polymerase**  
**101.626-12u – without *Taq* polymerase**

Visit [www.caredx.com](http://www.caredx.com) for  
**“Instructions for Use” (IFU)**

**Lot No.: 0R9**

**Lot-specific information**

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 3, 6, 8, 13, 14, 16 to 22, 24 to 30, 32, 34, 35 and 37 to 43 were available. The specificity of the primers in primer solutions 3, 6, 8, 13, 14, 16 to 19, 22, 29, 32, 42 and 43 were tested by separately adding one or two 5'-primers, respectively one or more 3'-primers. In primer solutions 20, 25, 26, 28, 34, 37 and 39 to 41 it was only possible to test the 5'-primers, the 3'-primers were not possible to be tested. In primer solutions 21, 24, 27, 30, 35 and 38 it was only possible to test the 3'-primers, the 5'-primers were not possible to be tested. In primer mixes 1, 5, 8, 9, 14, 22 and 29 one or two of the 5'-primers could not be tested, and in primer mixes 3, 7, 12, 17, 22, 23 and 29 one or two of the 3'-primers could not be tested. In addition, one or more 3'- and/or 5'-primers in primer solutions 9 and 23 were tested by separately adding one 5'-primer and/or one 3'-primer, respectively.



101.626-12 – including *Taq* polymerase  
101.626-12u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **0R9**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**CareDx AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

**Fax:** +46-8-717 88 18

**E-mail:** [orders-se@caredx.com](mailto:orders-se@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

**Distributed by:**

**CareDx Lab Solutions Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-653-78171

**Fax:** 610-344-7989

**E-mail:** [orders-us@caredx.com](mailto:orders-us@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

For information on CareDx distributors worldwide, contact **CareDx AB**.

